Broadly protective vaccines against known and preemergent human coronaviruses (HCoVs)
are urgently needed. To gain a deeper understanding of cross-neutralizing antibody …

There is an urgent need for vaccines and therapeutics to prevent and treat COVID-19.
Rapid SARS-CoV-2 countermeasure development is contingent on the availability of robust, …

Crimean-Congo hemorrhagic fever virus (CCHFV) is a World Health Organization priority
pathogen. CCHFV infections cause a highly lethal hemorrhagic fever for which specific …

Experimental monoclonal antibody (mAb) therapies have shown promise for treatment of
lethal Ebola virus (EBOV) infections, but their species-specific recognition of the viral …

Coronavirus disease 2019 (COVID-19) is a global health crisis caused by the novel severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and there is a critical need to …

While neutralizing antibodies are highly effective against ebolavirus infections, current
experimental ebolavirus vaccines primarily elicit species-specific antibody responses. Here, we …

The zoonotic transmission of hantaviruses from their rodent hosts to humans in North and
South America is associated with a severe and frequently fatal respiratory disease, hantavirus …

Most known SARS-CoV-2 neutralizing antibodies (nAbs), including those approved by the
FDA for emergency use, inhibit viral infection by targeting the receptor-binding domain (RBD) …

Convalescent plasma with severe acute respiratory disease coronavirus 2 (SARS-CoV-2)
antibodies (CCP) may hold promise as a treatment for coronavirus disease 2019 (COVID-19). …

Crimean-Congo hemorrhagic fever virus (CCHFV) is the most widespread tick-borne zoonotic
virus, with a 30% case fatality rate in humans. Structural information is lacking in regard to …